Device Designed for Super Selective Embolization

WESTMINSTER, CO (October 18, 2013) – Surefire Medical, Inc., today announced the launch of a new, enhanced infusion system – the Surefire Infusion System mT – designed to treat vessels as small as 2mm to 3.5mm in interventional direct-to-target embolization procedures. The mT incorporates Surefire’s new low profile, effortlessly deployed expandable tip technology for maximum dose delivery without reflux.

“The new Surefire Infusion System mT gives Interventional Radiologists greater ability to maximize targeted delivery in a wider range of patient candidates by enabling infusion into vessels as small as 2mm,” said Ryan Majoria, MD, Chief of Interventional Radiology and Interventional Oncology at Our Lady of the Lake Regional Medical Center. “In a recent case, there was no way I could have delivered any dose safely without the mT because it was a small vessel with slow flow in a very high risk territory.”

Enhancements to the newly designed mT infusion system catheter tip include:

  • Smooth catheter inner liner for consistent dose delivery
  • Thinner and more streamlined design for improved deployment and retraction
  • Optimized shape of the Surefire expandable tip for reliable infusion even in very tortuous anatomy
  • Sufficient antegrade flow maintained in vessels as small as 2 mm

Other Surefire Medical infusion systems, including the ST/LT, will also incorporate many of the enhancements.

“The advances our team implemented in the new Surefire Infusion System mT and our other products provide physicians with even greater assurance that targeted embolization procedures can be effectively deployed in difficult-to-treat patients who can now also benefit from direct-to-tumor therapies,” said Jim Chomas, President and CEO of Surefire Medical.

About Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. The Surefire Infusion System mT/ST/LT and specialty catheters have received regulatory approval in the U.S., Europe, and New Zealand. For more information, please visit www.surefire.local.


Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.